Research - Cambridge, England, United Kingdom
Milltons brings together patients and researchers in order to discover new therapeutic mechanisms to painful and life threatening, yet neglected, chronic illnesses. We do not patent any of our findings and focus on creating value instead. Though our interest is in neurodegenerative illnesses, we are happy to be inventive in any illness that is both poorly resolved and where we could impact patient's life today, rather than in the distant future. We have been discovering new therapeutic mechanisms since 2009 with experience in Ophthalmology, Diabetes and Gastrointestinal complications. We have over a decade of experience in very early detection and treatment of Diabetic Retinopathy. We are always on the lookout for creative researchers to collaborate with. We have built a digital research platform, eliminating geographic boundaries or bottle necks on sample size population. Current ongoing Research Projects: Cystic Fibrosis:We are studying the impact of moving the digestion from the intestine to the stomach. Objectives:1. To enhance nutrients absorption and reduce fatigue.2. To reduce the amount of digestive enzymes used in Cystic Fibrosis Patients. Retinal Neurodegeneration (RN):We want to establish if retinal neurodegeneration is an early biomarker of irreversible health deterioration in different chronic conditions.Objectives:1. To establish RN as mainstream diagnostic for conditions where it is already demonstrated (like Diabetic Retinopathy and Alzheimer's Disease).2. To study what other deteriorations can be predicted early through RN. International COVID 19 anxiety research:Objectives:1. To measure the impact of the excess anxiety (caused by COVID-19 general state of mind) on accelerating neurodegeneration in persons with Diabetes, with a focus on Diabetic Retinopathy.2. To test therapies in the earlier stages (anxiety or inflammation) and measure their impact on slowing down neurodegeneration. Contact us to find out more.
Gmail
Mobile Friendly
Google Cloud Hosting